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Trimetazidine in Postischemic Rat Hearts
Summary. The objective of this study was to test the hy-
pothesis that the bene~cial effect of trimetazidine during
re_ow of ischemic hearts is mediated by energy sparing and
ATP pool preservation during ischemia. Isolated rat hearts
(controls and rats treated with 1026 M trimetazidine, n 5 17
per group) underwent the following protocol: baseline per-
fusion at normal coronary _ow (20 minutes), low-_ow is-
chemia at 10% _ow (60 minutes), and re_ow (20 minutes).
We measured contractile function, O2 uptake, lactate re-
lease, venous pH and PCO2, and the tissue content of high-
energy phosphates and their metabolites. During baseline,
trimetazidine induced higher venous pH and lower PCO2
without in_uencing performance and metabolism. During
low-_ow ischemia, trimetazidine reduced myocardial per-
formance (P 5 0.04) and ATP turnover (P 5 0.02). During
re_ow, trimetazidine improved performance (91 6 6% ver-
sus. 55 6 6% of baseline), prevented the development of
diastolic contracture and coronary resistance, and reduced
myocardial depletion of adenine nucleotides and purines.
ATP turnover during low-_ow ischemia was inversely re-
lated to recovery of the rate-pressure product (P 5 0.002),
end-diastolic pressure (P 5 0.007), and perfusion pressure
(P 5 0.05). We conclude that trimetazidine-induced protec-
tion of ischemic-reperfused hearts is also mediated by en-
ergy sparing during ischemia, which presumably preserves
the ATP pool during re_ow.
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In recent years, trimetazidine (TMZ, 1-[(2,3,4-
trimethoxyphenyl) methyl] piperazine) has been pro-
posed as an antianginal and antiischemic agent [1]. Un-
like nitrates or Ca21 antagonists, this drug does not
in_uence coronary blood _ow nor myocardial O2 con-
sumption [2], thus presumably it protects energy me-
tabolism. TMZ, indeed, limits high-energy phosphate
depletion during ischemia [3], thereby reducing intra-
cellular acidosis without Ca21 blocking activity [4].
Furthermore, TMZ has no effect on glycolytic _ux [5]
and free radical formation [6], although the latter
~nding is controversial [7], but, nevertheless, it pro-
tects sarcolemmal mechanical resistance in reoxygen-
ated myocytes [8]. Taken together, these observations
suggest that TMZ exerts its effect at the level of mem-
brane ion exchange. However, studies aimed at assess-
ing the effect of TMZ on Na1,K1-ATPase [9] and on
mitochondrial Ca21 uptake [10] showed that this effect
occurs only for TMZ levels much higher than those that
protect the myocardium. Thus, despite extensive work,
the mechanism of action of this drug deserves further
investigation.
The crystalloid-perfused isolated heart is a valuable
model to extend our knowledge of the mechanism of
action of TMZ. In this model, the phenomena related to
the presence of blood, nervous system, and humoral
factors are ruled out. Furthermore, myocardial recov-
ery from low-_ow ischemia depends on residual coro-
nary _ow and on energy requirements during ischemia
[11]. If the low ATP situation secondary to high energy
demand with respect to supply is associated with sub-
stantial residual coronary _ow, the membrane-diffus-
able metabolites of ATP are lost, thereby delaying ATP
resynthesis during re_ow. The subsequent impairment
of recovery during re_ow apparently overrides the
protection afforded by free radical scavengers [12] and
control of the reoxygenation rate [13].
In this study we tested the hypothesis that protec-
tion of ischemic-reperfused hearts by TMZ is associ-
ated with energy sparing during ischemia: The ATP
pool is better preserved with reduced energy demand
during ischemia, and this improves recovery during
re_ow. To this aim, isolated rat hearts were exposed to
low-_ow ischemia and re_ow while monitoring  per-
formance and metabolism, either in the presence or
absence of 1026 M TMZ. We showed that TMZ im-
proves the recovery of contractile function after low-
_ow ischemia and that cardioprotection is correlated
with events related to energy sparing that occur dur-
ing ischemia.
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Materials and Methods
Heart perfusion
Male Sprague-Dawley rats (weighing 250–280 g) were
heparinized and anesthetized with sodium thiopental
(100 mg/kg). Hearts (average weight, 0.90 6 0.05 g)
were excised, immersed in isotonic saline (208C), and
mounted on the perfusion system [11]. The time re-
quired for these operations never exceeded 45 seconds
and was typically in the 15–30 second range. Langen-
dorff perfusion started immediately with Krebs-
Henseleit medium containing 2.0 mM free Ca21 and 11
mM glucose (pH 7.41 6 0.01, means 6 SE, 378C). When
required, 1026 M TMZ (Servier Laboratories, France)
was added to the medium, which was equilibrated at
PO2 5 670 6 6 mmHg and PCO2 5 36 6 1 mmHg in
membrane oxygenators [14]. A peristaltic pump (Gil-
son, France) delivered the medium at desired _ows to
the ~lter (8 lm pore size, 47 mm diameter, Nucleopore
Corp., Pleasanton, CA), preheater, and aortic cannula.
All perfusion system components, including the heart
chamber, oxygenator, _ow distribution valve box, and
preheater, were connected to a 1760 W external water
bath (Endocal, Neslab Instruments, Newington, NH)
kept at 37.58C. A latex balloon introduced into the left
ventricle was connected to a pressure transducer (Har-
vard Apparatus model 52-9966, Natick, MA) to monitor
performance. An additional transducer connected to
the aortic cannula provided the coronary perfusion
pressure. A cannula was inserted into the pulmonary
artery to collect the venous return and to monitor ve-
nous PO2 by an O2-sensing electrode (Yellow Springs,
Inc., model 5300 Oxygen Monitor, Yellow Springs, OH).
The investigation conforms with the Guide for the Care
and Use of Laboratory Animals published by the U.S.
National Institutes of Health (NIH publication no. 85-
23, revised 1985).
Experimental protocol
All hearts were divided into two groups: control
(Krebs-Henseleit medium only) and those thoroughly
perfused in the presence of 1026 M TMZ. Hearts were
stabilized for 20 minutes at _ow 5 15 mL/min for base-
line measurements. During this period the volume of
the intraventricular balloon was adjusted to an end-
diastolic pressure of 10 mmHg and was kept constant
thereafter. Then, hearts underwent low-_ow ischemia
for 60 minutes by reducing the _ow to 1.5 mL/min,
followed by 30 minutes reperfusion under the same
conditions as baseline (n 5 7 per group). Additional
hearts served to derive morphological data and to as-
sess structural and ultrastructural derangement (n 5
2 per group at the end of reperfusion, plus one heart at
the end of baseline). In other experiments hearts were
freeze-clamped either at the end of baseline (n 5 4 per
group) or at the end of ischemia (n 5 6 per group), to
measure tissue high-energy phosphates and their me-
tabolites.
Measurements
Myocardial performance was continuously monitored
by a LabView system (National Instruments, Austin,
TX) running on a Macintosh Quadra 700 (Apple, Cu-
pertino, CA). The measured parameters include end-
diastolic (EDP) and peak systolic (PSP) pressures,
maximal rate of pressure development (LVdP/dtmax),
coronary perfusion pressure (CPP), and venous PO2.
From these parameters we derived the heart rate
(HR), left-ventricle developed pressure (LVDP 5 PSP
2 EDP), and myocardial contractile work
(LVDP•HR). Venous [lactate] (Sigma Diagnostics, St.
Louis, MO) pH and PCO2 (Ciba Corning M238 Blood
Gas Analyzer, Milan, Italy) were measured at the end
of baseline, low-_ow ischemia, and re_ow. In addition,
the creatine kinase release during the ~rst 5 minutes of
re_ow was measured in two hearts per group using an
enzymatic test (Sigma Diagnostics, St. Louis, MO) op-
timized for maximal sensitivity.
To measure the myocardial level of high-energy
phosphates and their metabolites, after obtaining
hemodynamic data hearts were quickly (t , 1 s) frozen
with large aluminum clamps that were precooled at
liquid nitrogen temperature. Freeze-clamp was per-
formed simultaneously with the removal of the intra-
ventricular balloon because in separate experiments
(not shown) the levels  of ATP and phosphocreatine
were the same as those observed in hearts  freeze-
clamped with the balloon in the left ventricle. Frozen
tissue was extracted with 0.5 M perchloric acid, neu-
tralized, and assayed for ATP, phosphocreatine, ADP,
AMP, inosine-59-phosphate, adenosine, inosine, xan-
thine, hypoxanthine, urate, and creatine by HPLC
methods [15].
To assess the structural and ultrastructural de-
rangement at the end of re_ow, additional hearts were
arrested by perfusing them with 2.5% (v/v) ice-cold
glutaraldehyde. Arrested hearts were quickly im-
mersed in the same glutaraldehyde solution, then the
left ventricle was cut into 1–2 mm thick slices, mapped,
and processed for light microscopy (tetrazolium blue,
hematoxylin and eosin staining). Transmission electron
microscopy was performed on specimens from four dif-
ferent left ventricle sites per each heart. Sections were
stained with uranyl acetate and lead citrate, as de-
scribed previously [12], and ~nally were observed with
a CEM 902 (Zeiss Ikon, Germany) electron microscope.
To evaluate damage we used the semiquantitative
grading system, which is based on the established cri-
teria of myocardial ischemic injury [16]. Brie_y, this
system considers the following parameters: nuclear
margination and clumping of chromatin, mitochondrial
enlargement, changes in myocardial ~bers, interstitial
edema, and hemorrhage. We assigned scores from 1 (no
or mild changes) to 4 (marked or severe changes) to
each of these parameters, and then we averaged the
scores. Reference score 4 damage was obtained by ex-
posing an additional heart to 1 hour of anoxia followed
by reoxygenation as reported earlier [12].
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Calculations
Calculations included: (1) O2 uptake (VO2; from  the
difference between arterial and venous PO2, O2 solubil-
ity coef~cient [17], and actual coronary _ow); (2) lactate
release from [lactate] and _ow; (3) ATP turnover rate
as the sum of the two components yielding energy in
the form of ATP under the selected experimental con-
ditions, which are anerobic glycolysis, by assuming an
ATP-to-lactate ratio of 1.0, and oxidative metabolism,
by assuming a P/O ratio of 3 [14]; (4) total content of
adenine nucleotides and purines as the sum of ATP,
ADP, AMP, inosine-59-phosphate, adenosine, inosine,
xanthine, hypoxanthine, and urate; (5) energy charge,
as ([ATP] 1 0.5 [ADP])/([ATP] 1 [ADP] 1 [AMP]); and
(6) base excess from pH and PCO2 [18]. This parameter
allows the assessment of whether an apparently abnor-
mal pH value is due to changes in volatile (CO2) or ~xed
(H1) acidity.
Statistics
Data are expressed as the mean 6 SE. To detect inter-
actions between TMZ treatment and three consecutive
perfusion conditions (baseline, low-_ow ischemia, and
re_ow), we used two analysis of variance (ANOVA)
procedures (StatView, Abacus Concepts, Berkeley,
CA), depending on the variable being tested: two-way,
repeated measures ANOVA for variables available for
each heart under the three conditions; and factorial, six
groups ANOVA for variables such as the myocardial
metabolite content. In both cases, if the ANOVA test
was signi~cant (P , 0.05), the TMZ and control hearts
were compared using the Bonferroni/Dunnett multiple
comparison procedure, that is, by correcting the
signi~cance of the test for the number of comparisons.
The latter correction was not applied for variables
available or meaningful during low-_ow ischemia only.
Results
Mechanical performance
Figure 1 shows myocardial work (LVDP•HR) and
EDP during baseline, low-_ow ischemia, and re_ow.
TMZ did not signi~cantly affect myocardial function
during baseline (see also Table 1), but during low-_ow
ischamia TMZ depressed LVdP/dtmax, LVDP, and
LVDP•HR. During re_ow these variables were higher
in TMZ than control hearts. In addition, EDP and CPP
were lower in TMZ-treated hearts.
Metabolism
Table 1 shows that TMZ did not signi~cantly affect
VO2, neither during baseline nor during low-_ow is-
chemia,  but VO2 was  higher  in  TMZ hearts during
re_ow.  The high  coronary  _ow during baseline  and
re_ow led to excessive dilution of venous [lactate],
which was not detectable under right _ow conditions.
Therefore, the ATP turnover rate during baseline and
re_ow was calculated only from VO2, assuming that the
contribution of anerobic glycolysis was negligible. In
contrast, venous [lactate] was measurable in both
groups during low-_ow ischemia: It was less in TMZ
than in control hearts (1.10 6 0.07 vs. 1.35 6 0.05, n 5
13 per group, P 5 0.008).
Because _ow was the same in the two groups, differ-
ent venous [lactate] values implied different rates of
lactate release (1.62 6 0.10 vs. 1.98 6 0.08 lmoles / min,
P 5 0.008). Hence, the ATP turnover rate during low-
_ow ischemia was calculated from both lactate release
and VO2, as explained in Material and Methods. It was
higher in control than TMZ hearts (P 5 0.018). Fur-
thermore, TMZ transiently reduced acidosis and hy-
percapnia during baseline. Phosphocreatine tissue con-
tent was unchanged by TMZ, but the content of ATP,
total adenine nucleotides, and purines during re_ow
was higher in TMZ than in control hearts.
Myocardial damage
Light and electron microscopic analyses revealed mi-
nor alterations (average score ,1), without signs of
irreversible  myocardial damage  in  both  control and
TMZ hearts. Creatine kinase release during re_ow was
,0.1 U/L/min in both groups,  that is, ,1%  of that
observed during reoxygenation after 1 hour of anoxia.
Energy demand versus recovery
To test the hypothesis that cardioprotection elicited by
TMZ is partially mediated by energy sparing during
low-_ow ischemia, Figure 2 shows the correlation be-
tween the ATP turnover rate during low-_ow ischemia,
an index of energy demand, and LVDP ;sL HR during
re_ow, an index of mechanical recovery. The data ~t a
line with a negative slope (212.9 6 3.3, P 5 0.002, 95%
con~dence limits 220.0 to 25.7). Similar relations also
occur when substituting LVDP • HR with EDP (P 5
0.007), CPP (P 5 0.05), and LVdP/dtmax (P 5 0.01), but
not with VO2.
Discussion
Critique of the model
The aims of this study were (1) to determine the acute
effects of TMZ on myocardial function and metabolism
during low-_ow ischemia and re_ow, and (2) to assess
the correlations between bioenergetics during low-
_ow ischemia and recovery during re_ow. The experi-
mental conditions employed induced reproducible
myocardial dysfunction in control hearts without lead-
ing to arrest. Lack of blood in the perfusion medium
excluded possible effects of TMZ on neutrophil accu-
mulation [19] and on thrombin-induced platelet aggre-
gation [20]. Strict temperature control (6 0.5 8C), us-
ing the same volume of the intraventricular balloon,
the same coronary _ow, and the same O2 supply in
the two groups ruled out differences in loading con-
ditions. Because animals were not pretreated, these
observations relate to acute metabolic effects of TMZ
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on cardiac muscle. The TMZ-induced reduction of aci-
dosis and lower base excess during baseline perfusion
indicate that TMZ in_uences ~xed acids rather than
CO2 metabolism, in agreement with previous 23Na-
NMR studies that indicate TMZ affects the Na1/H1
antiport. [4]
We explored the properties of isolated hearts at the
TMZ concentration (1026 M) that was previously
ef~cient with regard to ischemia protection [5]. Of in-
terest, in that study rats were pretreated with TMZ (3
mg/kg body weight, twice daily for 5 days), but we
showed that 1026 M TMZ is protective regardless of
animal pretreatment. This concentration is within the
range of therapeutic blood levels in treated patients
with cardiovascular disorders [21]. A higher concentra-
tion (5 • 1024 M) of TMZ was used in studies aimed at
investigating electrophysiological properties in cardiac
myocytes [22]. Besides being unrealistic in clinical set-
tings, that concentration has already been shown to
exacerbate ischemic injury in isolated rat hearts [5].
Protective effects of TMZ
In this model TMZ protects postischemic hearts, espe-
cially early during re_ow. The protection may decrease
for prolonged  (.30-minute)  re_ow times, consistent
with the observation in isolated ventricular myocytes
that 3 • 1024 M TMZ slows the recovery of intracellular
pH [23]. Nevertheless, TMZ acutely protects myocar-
dial contractility (LVdP/dtmax, LVDP, and LVDP • HR).
In addition because the ventricular balloon volume re-
mained constant throughout the experiment, the lower
increase EDP indicates decreased diastolic contrac-
ture. Moreover, coronary _ow was the same in the two
groups; therefore, the lower CPP indicates less coro-
nary resistance in TMZ hearts. All these mechanical
improvements are accompanied by increased levels of
ATP, total adenine nucleotides and purines, but not
phosphocreatine. The latter feature is a consequence of
the lack of irreversible injury, as shown by electron
microscopy, and the observation that the sum of phos-
phocreatine 1 creatine decreases only for overt mem-
brane damage [24].
The present study indicates that a portion of the
bene~cial effect of TMZ is exerted through energy-
sparing during low-_ow ischemia. Decreased
LVDP•HR during low-_ow ischemia is accompanied
by lower lactate release, that is, a lower rate of anaero-
bic metabolism. Because aerobic metabolism is the
same in the two groups, the ATP turnover rate de-
creases to a greater extent in TMZ-perfused hearts.
Fig. 1. Time course of developed pressure (LVDP) • heart rate (HR) (upper panel) and of end-diastolic pressure (lower panel) dur-
ing the experimental protocol in control (solid line) and TMZ-treated (dotted line) hearts (n 5 7 per group). The inset shows enlarge-
ment relative to LVDP • HR at the end of low-_ow ischemia.
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TMZ and energy sparing
The mechanism underlying energy sparing during is-
chemia remains to be elucidated, but less acidosis is not
implied because it should increase, not decrease, con-
tractile function [25]. Furthermore, changes in pyru-
vate dehydrogenase are not likely because these
changes occur at TMZ concentrations much higher
than those that prevent ischemic contracture [26]. Fi-
nally, changes in glycolytic _ux regulation were ruled
out [5]. It is possible that the observed energy sparing
during ischemia shares some common mechanisms
with the recently reported TMZ-induced inhibition of
free fatty acid oxidation [27].
Irrespective of the mechanisms underlying energy
sparing, our results are consistent with the 31P-NMR
~nding that 6•1027 M TMZ improves phosphocreatine
and ATP levels during low-_ow ischemia [3]. Lack of
data on performance and the ATP metabolite level
during ischemia, not measurable with 31P-NMR tech-
niques, makes it dif~cult to understand why in that
study TMZ failed to improve postischemic perform-
ance. Indeed, ATP reconstitution during re_ow is lim-
ited by precursor availability rather than by cellular
phosphorylation capacity [28]. Furthermore, the intra-
cellular level of these precursors critically depends on
energy demand and coronary _ow during ischemia
[11].
The relationship between energy sparing during is-
chemia and recovery has a metabolic background. At
constant coronary _ow, low energy demand prevents
intracellular buildup of ATP catabolites, that is, ade-
nine nucleotides and purines [11]. Because some of
these are permeable through the cell membrane [29],
residual _ow selectively removes them, thereby de-
creasing their tissue levels during re_ow. Greater
availability of adenine nucleotides and purines early
during re_ow helps the heart to quickly resynthesize
ATP, thereby improving recovery [30]. This result is
obtained even from relatively small declines in the ATP
turnover rate: Using the data reported here, if the
3.5% decline in the ATP turnover rate is protracted for
60 minutes, the ~nal gain in ATP content can be calcu-
lated as (10.26 lmoles/minutes) 3 (60 minutes) 3
(3.5%) 5 21.5 lmoles/heart, which corresponds to .10
Table 1. Myocardial performance and metabolism at the end of baseline, low-_ow ischemia, and re_ow for control and TMZ hearts
Baseline Low _ow ischemia Re_ow
ANOVA
Parameter P Control TMZ Control TMZ Control TMZ
n 17 17 13 13 7 7
Heart rate (min21) .05 245 6 8 249 6 13 145 6 7 161 6 7 201 6 5 231 6 9
End-diastolic pressure .0007 10.4 6 0.4 9.6 6 0.2 12.5 6 0.7 11.8 6 0.6 52.7 6 8.2 24.6 6 3.3a
(mmHg)
LVdP/dtmax (mmHg/s) .002 3465 6 195 3288 6 111 1188 6 59 1016 6 43b 2418 6 209 3203 6 194a
Coronary pressure (mmHg) .01 72 6 2 66 6 1 20 6 1 15 6 1b 112 6 7 92 6 5a
Venous pO2 (mmHg) .03 158 6 20 150 6 25 13 6 3 13 6 4 220 6 65 62 6 30a
Developed pressure (mmHg) .006 139 6 6 130 6 6 51 6 2 39 6 2b 97 6 9 124 6 7a
Developed pressure • heart ,.0001 33.7 6 1.4 31.6 6 1.1 7.2 6 0.3 6.3 6 0.3b 19.5 6 1.9 28.5 6 1.7a
rate (mmHg • 103 / min)
O2 uptake (lmoles/min) .03 10.7 6 0.4 10.9 6 0.5 1.4 6 0.1 1.4 6 0.1 9.5 6 1.4 12.7 6 0.6a
ATP turnover rate .03 64.5 6 2.5 65.5 6 3.2 10.26 6 0.08 9.90 6 0.12b 57.0 6 7.3 76.3 6 3.7a
(lmoles/min)
Venous pH ,.0001 7.29 6 0.01 7.34 6 0.01a 7.04 6 0.02 7.09 6 0.02 7.32 6 0.02 7.33 6 0.03
Venous pCO2 (mmHg) ,.0001 47 6 1 41 6 1a 86 6 3 77 6 3b 44 6 2 43 6 3
Base excess, (mM) NS 21.9 6 0.2 22.4 6 0.1 21.8 6 0.2 21.8 6 0.2 22.3 6 0.2 22.2 6 0.1
n 4 4 6 6 7 7
ATP (lmoles/g dw) .003 17.4 6 0.8 21.9 6 1.3 12.3 6 1.9 13.4 6 1.2 12.5 6 1.8 18.2 6 1.9c
Phosphocreatine (lmoles/g NS 43.2 6 9.4 49.5 6 14.4 28.9 6 6.1 35.1 6 6.6 52.1 6 13.1 69.2 6 12.3
dw)
Total adenine nucleotides .01 27.3 6 1.4 34.4 6 2.0 23.0 6 2.6 26.2 6 1.6 21.4 6 2.5 29.8 6 2.9c
and purines (lmoles/g dw)
Energy charge .04 .830 6 .004 .826 6 .015 .778 6 .016 .758 6 .025 .818 6 .018 .811 6 .007
Phosphocreatine 1 NS 77.6 6 6.1 87.7 6 13.7 68.3 6 7.2 81.8 6 5.2 78.4 6 13.1 95.8 6 13.1
creatine (lmoles/g dw)
Mean 6 SE is reported for all available data.
aSigni~cantly different from control (two-way, repeated measure ANOVA followed by the Bonferroni/Dunnett multiple comparison test).
bSigni~cantly different from control (two-way, repeated measure ANOVA uncorrected for the number of comparisons, only for low-_ow ischemia
data).
cSigni~cantly different from control (one-way, six-group factorial ANOVA followed by the Bonferroni/Dunnett multiple comparison test).
NS 5 not signi~cant; dw 5 dry weight.
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times the actual tissue ATP content [11]. This consid-
eration also explains why comparable levels of TMZ
apparently do not have measurable effects for short
ischemia times [31].
Although any extrapolation to clinical settings
should be made with caution, the pharmacological pro-
tection elicited by TMZ on postischemic hearts seems
to involve several cell paths. These include improved
ATP synthesis secondary to increased mitochondrial
Ca21 uptake [10], limited acidosis through modulation
of the Na1/H1 antiport [4], and energy sparing during
ischemia (this study). In principle the last two effects
may be distinguished by withdrawing TMZ at the time
of re_ow. However, TMZ  activity might last longer
than its presence, if, for example, it is mediated by
inhibition of some enzymes.
Conclusions
One-micromolar TMZ signi~cantly protects ischemic-
reperfused hearts in this model. Although a major com-
ponent of this protection is linked to membrane ion
exchange, a signi~cant component is mediated by en-
ergy sparing during low-_ow ischemia, which protects
the ATP pool during re_ow.
Acknowledgments
Work supported by Servier Laboratories, France.
References
1. Detry JMR, Leclerq PJ. Trimetazidine European multicen-
ter study versus propranolol in stable angina pectoris: Con-
tribution of Holter electrocardiographic ambulatory moni-
toring. Am J Cardiol 1995;76:8B–11B.
2. Levy S. Combination therapy of trimetazidine with
diltiazem in patients with coronary artery disease. Am J
Cardiol 1995;76:12B–16B.
3. Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of
trimetazidine: 3P-NMR spectroscopy in the isolated rat
heart. Arch Internat Pharmacodyn Ther 1987;286:97–110.
4. Renaud JF. Internal pH, Na1, and Ca11 regulation by
trimetazidine during cardiac cell necrosis. Cardiovasc Drug
Ther 1988;1:677–686.
5. Boucher FR, Hearse DJ, Opie LH. Effects of trimetazidine
on ischemic contracture in isolated perfused rat hearts. J
Cardiovasc Pharmacol 1994;24:45–49.
6. Maupoil V, Rochette L. Evaluation of free radical and lipid
peroxide formation during global ischemia and reperfusion
in isolated rat heart. Cardiovasc Drug Ther 1988;2:615–621.
7. Guarnieri C, Muscari C. Bene~cial effects of trimetazidine
on mitochondrial function and superoxide production in the
cardiac muscle. Cardiovasc Drug Ther 1990;4:814–815.
8. Ruiz-Meana, M, Garcia-Dorado D, Julia M, Gonzalez MA,
Inserte J, Soler-Soler J. Pre-treatment with trimetazidine
increases sarcolemmal mechanical resistance in reoxygen-
ated myocytes. Cardiovasc Res 1996;587–592.
9. Hisatome I, Ishiko R, Tanaka Y, et al. Trimetazidine inhibits
Na1,K1-ATPase activity, and overdrives hyperpolarization
in guinea-pig ventricular muscles. Eur J Pharmacol
1991;195:381–388.
10. Guarnieri C, Finelli C, Zini M, Muscari C. Effects of
trimetazidine on the calcium transport and oxidative phos-
phorylation of isolated rat heart mitochondria. Basic Res
Cardiol 1997;92:90–95.
11. Samaja M, Motterlini R, Allibardi S, et al. Myocardial
metabolism and function  in  acutely ischemic and hypox-
emic isolated rat hearts. J Mol Cell Cardiol
1995;27:1213–1218.
12. Samaja M, Motterlini R, Santoro F, Dell’Antonio G, Corno A.
Oxidative injury in reoxygenated and reperfused hearts.
Free Radic Biol Med 1994;16:255–262.
13. Corno A, Samaja M, Casalini S, Allibardi S. The effects of
the rate of reoxygenation on the recovery of hypoxemic
hearts. J Thorac Cardiovasc Surg 1995;109:1250–1251.
14. Samaja M, Casalini S, Allibardi S, Corno A, Chierchia S.
Regulation of bioenergetics in O2-limited isolated rat hearts.
J Appl Physiol 1994;77:2530–2536.
15. Motterlini R, Samaja M, Tarantola M, Micheletti R, Bianchi
G. Functional and metabolic effects of propionyl-L-carnitine
in the isolated perfused hypertrophied rat heart. Mol Cell
Biochem 1992;116:139–145.
16. Davtyan HG, Corno A, Laks H, et al. Long-term neonatal
heart preservation. J Thorac Cardiovasc Surg 1988;96:
44–53.
17. Roughton FJW, Severinghaus JW. Accurate determination
of O2 dissociation curve of human above 98.7% saturation
with data on O2 solubility in unmodi~ed human blood from
08; to 378; C. J Appl Physiol 1973;35:861–869.
18. Thomas LJ. Algorithms for selected blood acid-base and
blood gas calculations. J Appl Physiol 1972;33:154–158.
19. Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine
inhibits neutrophils accumulation after myocardial ischemia
Fig. 2. Relation between the ATP turnover rate at the end of
low-_ow ischemia and the recovery of LVDP • HR at the end of
re_ow in control (empty symbols) and TMZ-treated (~lled sym-
bols) hearts (n 5 7 per group). When all data are taken to-
gether, they ~t a straight line: y 5 112.9 x 1 154, multiple r 5
0.75, signi~cance of the F-test P 5 0.002.
548 Allibardi et al.
and reperfusion in rabbits. J Cardiovasc Pharmacol 1993;
22:823–833.
20. Astarie-Dequeker C, Joulin Y, Devynck MA. Inhibitory ef-
fect of trimetazitidine on thrombin-induced aggregation and
calcium entry into human platelets. J Cardiovasc Pharma-
col 1994;23:410–407.
21. Royer RJ, Royer Morrot MJ, Bannwarth B, Giffard S, Har-
pey C. Evaluation des concentrations à l’état d’équilibre et
de la ~xation globulaire de la trimétazidine. Vastarel 20 mg
et l’ischémie myocardique. Gaz Med France 1984;91:69–70.
22. Fantini E, Athias P, Demaison L, Grynberg A. Protective
effects of trimetazidine on hypoxic cardiac myocytes from
the rat. Fundam Clin Pharmacol 1997;11:427–439.
23. Lagadic-Gossmann D, Le Prigent K, Feuvray D. Effects of
trimetazidine on pHi regulation in the rat isolated ventricu-
lar myocyte. Br J Pharmacol 1996;117:831–838.
24. Reimer KA, Jennings RB, Hill ML. Total ischemia in dog
hearts, in vitro. 2. High energy phosphate depletion and
associated defects in energy metabolism, cell volume regu-
lation, and sarcolemmal integrity. Circ Res 1981;49:901–911.
25. Zhou HZ, Malhotra D, Shapiro JI. Contractile dysfunction
during metabolic acidosis: Role of impaired energy metabo-
lism. Am J Physiol 1991;261:H1481–H1486.
26. Veitch K, Maisin L, Hue L. Trimetazidine effects on the
damage to mitochondrial functions caused by ischemia and
reperfusion. Am J Cardiol 1995;76:25B–30B.
27. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid
oxidation  in  the heart (abstr). J  Mol  Cell Cardiol 1998;
30:A112.
28. Rossi A, Lortet S. Energy metabolism patterns in mammal-
ian myocardium adapted to chronic physiopathological con-
ditions. Cardiovasc Res 1996;31:163–171.
29. Bak  MI, Ingwall JS.  Acidosis during ischemia promotes
adenosine triphosphate resynthesis in postischemic rat
heart. J Clin Invest 1994;93:40–49.
30. Samaja M, Allibardi S, de Jonge R, Chierchia S. High-en-
ergy phosphates  metabolism and  recovery in reperfused
ischemic hearts. Eur J Clin Invest 1998, in press.
31. Koning MM, Krams R, Xiao CS, et al. Intracoronary
trimetazidine does not improve recovery of regional func-
tion in a porcine model of repeated ischemia. Cardiovasc
Drug Ther 1996;7:801–807.
Trimetazidine in Postischemic Rat Hearts 549

